As such, niclosamide is found to be potentially effective for the treatment of coronavirus in patients and has been approved in the U.S., Italy, France, and few other countries where there is a high prevalence of active COVID-19 patients. Read Report Overview – https://www.transparencymarketresearch.com/anthelmintic-drugs-market.html
Due to the approval of niclosamide, companies in the anthelmintic drugs market are increasing their efficacy in AI-driven drug discovery methods to capitalize on revenue generation opportunities. Companies in the anthelmintic drugs market are taking efforts to conduct clinical trials in existing drugs that may be useful in coronavirus treatment. Companies in the anthelmintic drugs market are entering into strategic collaborations in order to find new treatments for ascaris lumbricoides (Roundworm) infection. This explains why the revenue for roundworm target pathogen is estimated to dictate the highest value in the anthelmintic drugs market, resulting in anticipated revenue generation of ~US$ 4 Bn by the end of 2030. The growing awareness about soil-transmitted infections and filarial infections in humans is bolstering innovations in anthelmintic drugs.
An alarmingly right prevalence of parasitic worm infections in humans has forced companies in the anthelmintic drugs market to increase their R&D capabilities for new drug candidates. For instance, in December 2019, Bayer Animal Health — a global provider of innovative solutions for animal health, revealed that the company is increasing its research efforts to provide promising anthelmintic drug candidates for the EU-sponsored collaboration called Project HELP (Helminth Elimination Platform) meant for human treatment. Request for Analysis of COVID-19 Impact on Anthelmintic Drugs Market -https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=50688
Sponsored Collaborations Fuel Research in New Drug Candidates for Soil-transmitted Infections Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=50688
Plant-based products are being highly publicized for the development of anthelmintic drugs that are capable of treating nematodes. Currently, intestinal parasitic nematodes are a serious issue in human as well as animals. As such, animals dominate a higher revenue share as compared to humans in the anthelmintic drugs market, where the market is slated to progress at a CAGR of ~5% during the forecast period. However, anthelmintic drug resistance in humans and animals is a challenge for pharmaceutical companies. Hence, companies are using medicinal plant ingredients for the discovery of new anthelmintic drugs. Biologically Active Substances of Medicinal Plants Hold Promising Potentials for Drug Discovery
Combination Therapy Awaits Confirmed Clinical Trials to Deploy Widespread Adoption in Veterinary Clinics Request for Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=50688 Companies in the anthelmintic drugs market are increasing their research efforts to study the biologically active substances of medicinal plants that possess drug-like properties and hold promising potentials for the treatment of intestinal parasitic nematodes in human as well as animals. As such, medicinal plant-derived drugs, such as artemether, tiopropium and galantamine are generating revenue streams for pharmaceutical companies.
News Highlights Games
- Headline: Anthelmintic Drug Market: Launch and Approval of Anthelmintic Products by Key Players to Boost the Global Market
- Check all news and articles from the Gaming news updates.